Clinical characteristics of the patients with JIA before and after ASCT
| Patient (sex) | Onset age (years) | Onset form | ASCT (age) | Follow up (months) | Improvement over baseline (%) at last follow up | Present drug treatment | |
|---|---|---|---|---|---|---|---|
| 1(F) | 1 | Sys | 6 y 7 mo | 48 | 70 | None | Transient infection related relapse at 24 mo |
| 2(F) | 3 | Poly | 7 y 9 mo | 36 | 70 | None | Remission |
| 3(M) | 3 6 mo | Sys | 11 y 2 mo | 36 | 50 | Naprosyne | Transient infection related relapse at 12 mo, partial responder |
| 4(F) | 5 y 2.5 mo | Sys | 11 y 2 mo | 24 | 70 | None | Transient infection related relapse at 5 mo |
| 5(M) | 4 | Sys | 10 y 6 mo | 24 | 70 | None | Remission |
| 6(M) | 5 | Sys | 9 y 4 mo | 24 | 70 | None | Transient relapse at 14 mo (after vaccination) |
| 7(F) | 3 | Sys | 14 y 2 mo | 5 | Fatal MAS at 5 mo | ||
| 8(M) | 5 | Poly | 12 y 2 mo | 26 | 50 | None | Remission |
| 9(M) | 4 y 1 mo | Sys | 13 y 6 mo | 24 | 70 | Low steroids | Remission |
| 10(M) | 3 | Poly | 8 y 1 mo | 10 | 70 | Low steroids | Remission |
| 11(F) | 7 y 7 mo | Sys | 10 y 7 mo | 16 | 70 | None | Remission |
| 12(M) | 1 y 2 mo | Sys | 5 y 10 mo | 8 | 0 | Steroids, MTX, cyclophos. pulse | Persistent relapse |